The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
about
SATB2 augments ΔNp63α in head and neck squamous cell carcinomaEvidence for a direct involvement of hMSH5 in promoting ionizing radiation induced apoptosisNegative feedback control of HIF-1 through REDD1-regulated ROS suppresses tumorigenesisHOXB13 promotes ovarian cancer progressionOncogenic Intra-p53 Family Member Interactions in Human CancersBiomarkers in triple negative breast cancer: A reviewChemotherapy-enhanced inflammation may lead to the failure of therapy and metastasisTBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast CancerEfficacy of neoadjuvant Cisplatin in triple-negative breast cancerThe role of epigenetics in resistance to Cisplatin chemotherapy in lung cancerp73 as a pharmaceutical target for cancer therapyA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsA microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma.The integrin alpha(v)beta(3-5) ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER(+) and erbB2(+) breast cancers.TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.∆N-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites.The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancerChronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancerISG20L1 is a p53 family target gene that modulates genotoxic stress-induced autophagy.YAP accelerates Aβ(25-35)-induced apoptosis through upregulation of Bax expression by interaction with p73.Triple-negative breast cancer: role of specific chemotherapy agentsKPT-330 has antitumour activity against non-small cell lung cancer.Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacyMolecular features of the basal-like breast cancer subtype based on BRCA1 mutation statusMechanistic and Treatment Implications of DeltaNp63 Expression in a Rare Case of Metastatic HidradenocarcinomaDeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistanceCellular responses to Cisplatin-induced DNA damage.Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of originBRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinRegulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase betaTreatment options for patients with triple-negative breast cancerGenome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women.Phosphorylation of ΔNp63α via a novel TGFβ/ALK5 signaling mechanism mediates the anti-clonogenic effects of TGFβ.c-Abl phosphorylation of ΔNp63α is critical for cell viabilityMinireview: Basal-like breast cancer: from molecular profiles to targeted therapies
P2860
Q24299322-3A7E5FE8-1B1E-4F31-98DA-FF3C445A711CQ24310554-B7B2D3A3-2E33-4C97-BAA7-E67C9C3143B6Q24620427-CE191B40-CEE5-4238-9072-9917D10F591FQ24675458-6794107C-6A8C-40B3-B9B2-53221C1AF2BDQ26749382-17AE1B53-941E-49ED-AF89-8F4AA0DC1150Q26775094-64B3D826-9729-4B43-9B33-FE1162109382Q26858839-94671929-F1EA-43EF-9AC1-990B853B74DFQ27853147-0CCD48E0-95F3-4276-9143-6D3405CEB579Q28372484-A31448F9-FE5C-43F7-ABC2-63AB5FAA6B5BQ28387891-40D0DD24-A55B-4538-B765-9A533E57F306Q28611414-79546EA3-DC4D-4901-B9AD-C58EB04845F5Q30253017-FDF4C22A-2267-4981-ACBC-5765A4A654A7Q30497990-36A0CC3F-FC25-47B1-BB05-3E7DA7E8C4A1Q30992805-508FB60D-2FAC-4E42-B7AF-AAA980D578DFQ33358710-ED0A39FF-D2ED-49C9-9415-79A6DCA8103CQ33441772-D48E2171-0829-4DEC-8E45-0B720E409CE5Q33649918-5CED767C-F366-42FC-9570-A3E3B0EC01C3Q33688548-1D470C89-3CBE-4FCD-A679-18C930177C35Q33783151-EF9C0647-D945-43C9-973A-41AA69A70B17Q33788519-2A858473-3B4F-41A4-959B-05CD70CF773FQ33864174-E344CF2F-1B42-473D-900E-DE8098A65EE7Q33896065-E970BA19-2A14-4AC5-AE30-C796DD3A4435Q33900930-FF11BD31-FB35-4679-B4F4-B3AA571AB791Q33918079-CA31C02A-C7BC-45B3-AA2D-0C2CF2A5377DQ34005179-231834AF-99C1-44BC-ACE3-59D68C09EA31Q34038170-0A6CAA17-D9A5-43D4-968D-8ECCD8AABB6AQ34054713-6E02EAA3-3FCA-4585-B6F8-81C249EE8B88Q34067050-51509913-BF61-4738-B5ED-F175E8F3FE73Q34089685-103FF7B9-197F-429C-A2A8-8299312F0D3EQ34123261-A171B60E-75E3-4B87-9C99-F339DF273E1CQ34134454-6E33624B-E3AC-4E3F-BF37-BC1CEC6D8E31Q34204273-32DD78CC-2CE2-4BEB-AC62-245048984FC3Q34236112-565DDEDC-E6E6-4758-A57B-B930F8BFB971Q34331406-AEC29785-A759-45C6-915F-63E88FA240F8Q34362370-721DCCBB-BFAB-40D0-BA33-360BB9D48A9BQ34382716-CB5AA83C-E199-4BC8-B148-320CF4197EB0Q34421158-84984E85-470B-4DB9-8540-B395807F5E13Q34482997-A4854D96-3031-4B82-AFE8-8734ED6A91C4Q34546315-2CE7361E-9CAD-4A66-8AE7-1CB2C58630DCQ34562257-EBD5F61F-EDB4-4D85-ADD4-F7C881A14682
P2860
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The p63/p73 network mediates c ...... bset of primary breast cancers
@ast
The p63/p73 network mediates c ...... bset of primary breast cancers
@en
type
label
The p63/p73 network mediates c ...... bset of primary breast cancers
@ast
The p63/p73 network mediates c ...... bset of primary breast cancers
@en
prefLabel
The p63/p73 network mediates c ...... bset of primary breast cancers
@ast
The p63/p73 network mediates c ...... bset of primary breast cancers
@en
P2093
P2860
P356
P1476
The p63/p73 network mediates c ...... bset of primary breast cancers
@en
P2093
Chee-Onn Leong
Dennis Sgroi
Leif W Ellisen
Maurice Phillip DeYoung
Nick Vidnovic
P2860
P304
P356
10.1172/JCI30866
P407
P577
2007-04-19T00:00:00Z